Schering-Plough Corporation 1997 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1997, for Schering-Plough Corporation, a holding company incorporated in New Jersey. The Company operates globally in the discovery, development, manufacturing, and marketing of pharmaceutical and health care products. As of January 30, 1998, there were 732,902,378 common shares outstanding with an aggregate market value of approximately $53 billion held by non-affiliates. The Company employed approximately 22,700 people worldwide.
Key Financial Metrics
Consolidated sales for 1997 totaled $6,778 million, an increase from $5,656 million in 1996. Research and development expenditures were $847 million, representing approximately 13% of consolidated sales. Specific sales by major product groups for 1997 (in millions) were:
- Allergy/Respiratory: $2,708
- Anti-infective and Anticancer: $1,156
- Other Pharmaceuticals: $649
- Cardiovasculars: $637
- Dermatologicals: $571
- Animal Health: $389
- Foot Care: $300
- OTC: $208
- Sun Care: $148
Note: The filing text incorporates the Consolidated Balance Sheets, Statements of Income, and Cash Flows by reference to the 1997 Annual Report to Shareholders. Consequently, specific values for net profit, operating margins, total debt, and free cash flow are not explicitly stated in the provided text.
Material Changes
The most significant operational change in 1997 was the acquisition of the worldwide animal health operations of Mallinckrodt Inc. in June 1997. The acquisition was recorded at a cost of approximately $490 million, including assumed debt and direct costs. This transaction contributed to the growth in the Animal Health segment, which saw sales rise from $196 million in 1996 to $389 million in 1997. Additionally, the Allergy/Respiratory segment grew significantly, driven by products such as CLARITIN, increasing sales from $2,113 million to $2,708 million.
Outlook, Risks, and Contingencies
Legal Proceedings: The Company faces significant litigation risks:
- DES Litigation: Defendants in 185 lawsuits involving ~730 plaintiffs regarding synthetic estrogens, with total claims exceeding $2 billion. Management believes material liability in excess of accrued amounts is remote.
- Antitrust Actions: Defendant in over 160 antitrust actions alleging price-fixing and conspiracy. A federal class action was settled for $22.1 million. The FTC is investigating potential price-fixing conspiracies.
- Patent Disputes: Geneva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) for a generic version of Claritin, challenging the Company's patents. Schering-Plough has filed suit alleging willful infringement.
- Environmental: Involved in Superfund proceedings as a potentially responsible party (PRP). Management believes material liability in excess of accrued amounts is remote.
Regulatory and Market Risks: The Company is subject to strict FDA regulations and international government-mandated cost-containment programs, including price cuts and restrictions on physician prescriptions. Fluctuations in foreign currency exchange rates also impact consolidated results.
Investor Verification Checklist
- Verify the full Consolidated Statements of Income and Cash Flows in the 1997 Annual Report to Shareholders to confirm net income, operating margins, and liquidity positions not detailed in this text.
- Review the status of the FTC investigation into prescription drug price-fixing and the outcome of the Claritin patent litigation against Geneva Pharmaceuticals.
- Assess the integration progress and financial performance of the acquired Mallinckrodt animal health operations.
- Monitor the accruals and potential exposure related to the 185 DES lawsuits and Superfund environmental proceedings.
- Confirm the impact of managed care pricing pressures on the Allergy/Respiratory segment, which accounts for the largest portion of sales.